| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CHKa |
| Uniprot No | P35790 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-457aa |
| 氨基酸序列 | MKTKFCTGGEAEPSPLGLLLSCGSGSAAPAPGVGQQRDAASDLESKQLGG QQPPLALPPPPPLPLPLPLPQPPPPQPPADEQPEPRTRRRAYLWCKEFLP GAWRGLREDEFHISVIRGGLSNMLFQCSLPDTTATLGDEPRKVLLRLYGA ILQMRSCNKEGSEQAQKENEFQGAEAMVLESVMFAILAERSLGPKLYGIF PQGRLEQFIPSRRLDTEELSLPDISAEIAEKMATFHGMKMPFNKEPKWLF GTMEKYLKEVLRIKFTEESRIKKLHKLLSYNLPLELENLRSLLESTPSPV VFCHNDCQEGNILLLEGRENSEKQKLMLIDFEYSSYNYRGFDIGNHFCEW MYDYSYEKYPFFRANIRKYPTKKQQLHFISSYLPAFQNDFENLSTEEKSI IKEEMLLEVNRFALASHFLWGLWSIVQAKISSIEFGYMDYAQARFDAYFH QKRKLGV |
| 预测分子量 | 76 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CHKα(胆碱激酶α)重组蛋白研究的参考文献示例，内容基于典型研究方向整理：
1. **文献名称**：*Expression and Purification of Recombinant Human Choline Kinase α for Structural Studies*
**作者**：Smith J. et al.
**摘要**：本研究报道了人源CHKα的全长重组表达及纯化方法，利用大肠杆菌表达系统获得高纯度蛋白，并通过X射线晶体学解析其三维结构，揭示了ATP结合域的关键特征。
2. **文献名称**：*Functional Characterization of Recombinant CHKα in Cancer Cell Proliferation*
**作者**：Lee H. & Kim S.
**摘要**：通过哺乳动物细胞系表达重组CHKα，证实其酶活性在癌细胞磷脂代谢中的关键作用，并证明其抑制剂可显著降低肿瘤细胞生长速率。
3. **文献名称**：*Development of a High-Throughput Assay for CHKα Activity Using Recombinant Protein*
**作者**：Garcia R. et al.
**摘要**：构建重组CHKα的荧光标记版本，建立高通量酶活检测方法，用于筛选潜在抗癌化合物，验证了多个小分子抑制剂的体外效果。
4. **文献名称**：*Role of Recombinant CHKα in Lipid Droplet Formation in Hepatocytes*
**作者**：Wang Y. et al.
**摘要**：利用杆状病毒系统表达重组CHKα，发现其过表达促进肝细胞脂滴生成，提示其在非酒精性脂肪肝疾病中的潜在调控机制。
**注**：以上文献为示例性内容，实际引用请根据具体研究通过学术数据库核实。若需真实文献，建议检索PubMed或Web of Science，使用关键词 "choline kinase alpha recombinant" 或 "CHKA expression"。
CHKα (Choline Kinase Alpha) is a key enzyme in the choline metabolism pathway, responsible for catalyzing the phosphorylation of choline to phosphocholine, a critical step in the biosynthesis of phosphatidylcholine (PC), a major component of cell membranes. Dysregulation of CHKα has been implicated in various cancers, as elevated CHKα activity is associated with increased cell proliferation, survival, and metastasis. Its overexpression in tumors, such as breast, lung, and colorectal cancers, correlates with poor prognosis, making it a promising therapeutic target. CHKα contains conserved catalytic and choline-binding domains, and its activity is modulated by interactions with other metabolic enzymes.
Recombinant CHKα proteins are engineered using expression systems like *E. coli* or mammalian cell lines to ensure proper folding and post-translational modifications. These proteins retain enzymatic activity and structural integrity, enabling functional studies. Researchers employ recombinant CHKα to investigate its role in oncogenesis, screen small-molecule inhibitors, and dissect signaling pathways linked to lipid metabolism. For instance, inhibitors targeting CHKα’s ATP-binding site have shown anti-tumor effects in preclinical models, highlighting its therapeutic potential.
Additionally, recombinant CHKα serves as a tool for diagnostic applications, such as detecting autoantibodies in cancer patients. Its production typically involves affinity tags (e.g., His-tag) for purification and detection. Studies using recombinant CHKα have advanced understanding of metabolic reprogramming in cancer and facilitated drug development. By providing a consistent, scalable source of active enzyme, recombinant CHKα accelerates both basic research and translational efforts aimed at targeting choline metabolism for cancer treatment.
×
